Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 13,050 shares of the company's stock, valued at approximately $258,000.
A number of other hedge funds also recently made changes to their positions in the business. New York State Common Retirement Fund raised its stake in shares of Kiniksa Pharmaceuticals by 12.4% during the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after purchasing an additional 1,680 shares during the period. Peregrine Capital Management LLC raised its stake in shares of Kiniksa Pharmaceuticals by 1.8% during the 4th quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company's stock worth $4,827,000 after purchasing an additional 4,361 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the period. SG Americas Securities LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth $355,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 1.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company's stock worth $3,947,000 after purchasing an additional 3,673 shares during the period. 53.95% of the stock is currently owned by institutional investors.
Kiniksa Pharmaceuticals Stock Up 1.1 %
Kiniksa Pharmaceuticals stock traded up $0.24 during midday trading on Friday, reaching $21.51. The stock had a trading volume of 821,071 shares, compared to its average volume of 629,938. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The firm's 50-day moving average price is $19.76 and its 200 day moving average price is $22.39. The firm has a market capitalization of $1.55 billion, a PE ratio of -153.63 and a beta of 0.48.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to analysts' expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm's quarterly revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.35 EPS. Equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Analyst Ratings Changes
Separately, Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $36.60.
View Our Latest Research Report on Kiniksa Pharmaceuticals
Insider Buying and Selling at Kiniksa Pharmaceuticals
In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares of the company's stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 54.57% of the company's stock.
About Kiniksa Pharmaceuticals
(
Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
